Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT ID: NCT00241514

Last Updated: 2011-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

334 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Study Completion Date

2003-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess the efficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GERD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esomeprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent.
* Completed the SH-NEN-0001 study with relief of upper GI symptom. Relief is defined as "last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period".
* A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs.
* Daily NSAID treatment dose and type: (Must have been stable for at least 9 weeks prior to inclusion and; Are expected to remain stable for the duration of the study. and; Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally).
* Hp negative on Histology performed at baseline endoscopy in the study SHNEN- 0001.

Exclusion Criteria

* Discontinuation from study SH-NEN-0001
* Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation.
* Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs.
* Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator.
* Need for continuous concomitant therapy with: (Anticoagulants; Corticosteroids at doses higher than explained under inclusion criterion)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca Nexium Medical Sciences Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Tucson, Arizona, United States

Site Status

Research Site

Anaheim, California, United States

Site Status

Research Site

Orange, California, United States

Site Status

Research Site

San Francisco, California, United States

Site Status

Research Site

Bradenton, Florida, United States

Site Status

Research Site

Clearwater, Florida, United States

Site Status

Research Site

Fort Lauderdale, Florida, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

South Miami, Florida, United States

Site Status

Research Site

West Palm Beach, Florida, United States

Site Status

Research Site

Zephyrhills, Florida, United States

Site Status

Research Site

Conyers, Georgia, United States

Site Status

Research Site

Newburgh, Indiana, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Winston-Salem, North Carolina, United States

Site Status

Research Site

Tulsa, Oklahoma, United States

Site Status

Research Site

Tipton, Pennsylvania, United States

Site Status

Research Site

Norfolk, Virginia, United States

Site Status

Research Site

Virginia Beach, Virginia, United States

Site Status

Research Site

Alleur, , Belgium

Site Status

Research Site

Ans, , Belgium

Site Status

Research Site

Beernem, , Belgium

Site Status

Research Site

Betekom, , Belgium

Site Status

Research Site

Bottelare, , Belgium

Site Status

Research Site

Braine-l'Alleud, , Belgium

Site Status

Research Site

Buizingen, , Belgium

Site Status

Research Site

Duffel, , Belgium

Site Status

Research Site

Durnal, , Belgium

Site Status

Research Site

Erembodegem, , Belgium

Site Status

Research Site

Genk, , Belgium

Site Status

Research Site

Ghent, , Belgium

Site Status

Research Site

Herentals, , Belgium

Site Status

Research Site

Lambermont, , Belgium

Site Status

Research Site

Leut, , Belgium

Site Status

Research Site

Liège, , Belgium

Site Status

Research Site

Linkebeek, , Belgium

Site Status

Research Site

Maasmechelen, , Belgium

Site Status

Research Site

Massemen, , Belgium

Site Status

Research Site

Merelbeke, , Belgium

Site Status

Research Site

Natoye, , Belgium

Site Status

Research Site

Nivelles, , Belgium

Site Status

Research Site

Oud-Heverlee, , Belgium

Site Status

Research Site

Seraing, , Belgium

Site Status

Research Site

Soignies, , Belgium

Site Status

Research Site

Vorst (Brussels), , Belgium

Site Status

Research Site

Waremme, , Belgium

Site Status

Research Site

Zoersel, , Belgium

Site Status

Research Site

Zolder, , Belgium

Site Status

Research Site

Albens, , France

Site Status

Research Site

Angers, , France

Site Status

Research Site

Dambach-la-Ville, , France

Site Status

Research Site

Dommartin-les-touls, , France

Site Status

Research Site

Fontaine-lès-Dijon, , France

Site Status

Research Site

Gesté, , France

Site Status

Research Site

Gémenos, , France

Site Status

Research Site

Husseren-Wesserling, , France

Site Status

Research Site

La Regrip, , France

Site Status

Research Site

Le Pian-Médoc, , France

Site Status

Research Site

Lille, , France

Site Status

Research Site

Lyon, , France

Site Status

Research Site

Maromme, , France

Site Status

Research Site

Mont-de-Marsan, , France

Site Status

Research Site

Montingy Les Metz, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Saint-Ouen, , France

Site Status

Research Site

Strasbourg, , France

Site Status

Research Site

Tarare, , France

Site Status

Research Site

Berlin, , Germany

Site Status

Research Site

Bernau, , Germany

Site Status

Research Site

Bochum, , Germany

Site Status

Research Site

Cologne, , Germany

Site Status

Research Site

Dresden, , Germany

Site Status

Research Site

Dresden-Test, , Germany

Site Status

Research Site

Erfurt, , Germany

Site Status

Research Site

Erlangen, , Germany

Site Status

Research Site

Genthin, , Germany

Site Status

Research Site

Herne, , Germany

Site Status

Research Site

Kelkheim, , Germany

Site Status

Research Site

Künzing, , Germany

Site Status

Research Site

Lienen, , Germany

Site Status

Research Site

Lüdenscheid, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

Münster, , Germany

Site Status

Research Site

Paderborn, , Germany

Site Status

Research Site

Passau, , Germany

Site Status

Research Site

Potsdam, , Germany

Site Status

Research Site

Ratingen, , Germany

Site Status

Research Site

Regensburg, , Germany

Site Status

Research Site

Ribnitz-Damgarten, , Germany

Site Status

Research Site

Saarbrücken, , Germany

Site Status

Research Site

Salzgitter, , Germany

Site Status

Research Site

Wangen, , Germany

Site Status

Research Site

Wiesbaden, , Germany

Site Status

Research Site

Wolmirstedt, , Germany

Site Status

Research Site

Békéscsaba, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Dunaújváros, , Hungary

Site Status

Research Site

Szentes, , Hungary

Site Status

Research Site

Szombathely, , Hungary

Site Status

Research Site

Vác, , Hungary

Site Status

Research Site

Veszprém, , Hungary

Site Status

Research Site

Barcelona, , Spain

Site Status

Research Site

Getafe, , Spain

Site Status

Research Site

Guadalajara, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Mérida, , Spain

Site Status

Research Site

Palma de Mallorca, , Spain

Site Status

Research Site

San Sebastián(Guipuzcoa), , Spain

Site Status

Research Site

Seville, , Spain

Site Status

Research Site

Torrelavega, , Spain

Site Status

Research Site

Valencia, , Spain

Site Status

Research Site

Viladecans, , Spain

Site Status

Research Site

Zaragoza, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium France Germany Hungary Spain

References

Explore related publications, articles, or registry entries linked to this study.

Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Langstrom G, Naesdal J, Yeomans ND; NASA/SPACE author group. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther. 2007;9(1):R17. doi: 10.1186/ar2124.

Reference Type DERIVED
PMID: 17391505 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SH-NEN-0002

Identifier Type: -

Identifier Source: secondary_id

D9617C00002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Gastric Ulcers
NCT00629512 COMPLETED PHASE3
Nexium Dyspepsia/AST
NCT00251914 COMPLETED PHASE3
Ulcer Prevention II
NCT00629928 COMPLETED PHASE3